Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
Each line starts at 100 so growth is directly comparable
| Metric | VSTM | DNA |
|---|---|---|
| Price | $8.27 | $11.47 |
| Change today | ▲ 6.65% | ▼ 7.57% |
| Market cap | $748.51M | $772.39M |
| Return, 3 months | +53.1% | +17.9% |
| Return, year to date | +7.1% | +38.0% |
| Return, 1 year | -7.6% | -28.7% |
| P/E (TTM) | -3.4 | -2.3 |
| P/B | 15.0 | 1.8 |
| P/E percentile vs own 5y | 2nd | 30th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +1,775.4% | -48.5% |
| Net profit growth (YoY) | -33.7% | +22.5% |
| Gross margin | 86.4% | 68.0% |
| Operating margin | -182.6% | -228.6% |
| Net margin | -231.6% | -219.6% |
| Return on equity | -471.2% | -56.3% |
| Analyst target vs. price | +81.5% | -39.0% |
| Analyst buy share | 100% | 0% |
| RSI (14) | 60 | 57 |
| 30-day volatility | 53.1% | 125.7% |
| Max drawdown, 1 year | -67.6% | -66.0% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Buy | Sell |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
